- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 6, 2023
Highlights
- Market Cap
- $103.22M
- Enterprise Value
- $87.21M
- EPS (TTM)
- -$11.21
- Total Revenue (TTM)
- $3.84M
- Gross Profit (TTM)
- $3.19M
- EBITDA (TTM)
- -$78.53M
- Year Range
- $5.20 - $55.89
- Target Price
- $20.29
- ROA (TTM)
- -61.81%
- ROE (TTM)
- -94.87%
- Avg. Volume (1M)
- 194K
- Avg. Volume Value (1M)
- $2.47M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KRRO Performance Chart
Frequency Therapeutics Inc (KRRO) is up 29.5% since the beginning of the year. At $10 per share, KRRO is trading 81.4% below its 52-week high of $56.
Loading charts...
Compare this symbol against anything
Returns By Period
Frequency Therapeutics Inc (KRRO) has returned 29.46% so far this year and -25.13% over the past 12 months.
Frequency Therapeutics Inc
- 1D
- -0.77%
- 1M
- -25.93%
- 6M
- -22.21%
- YTD
- 29.46%
- 1Y
- -25.13%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -11.10%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
KRRO Monthly Returns History
Based on dividend-adjusted daily data since Nov 6, 2023, KRRO's average daily return is +0.33%, while the average monthly return is +10.18%. At this rate, an investment would double in approximately 0.6 years.
Historically, 45% of months were positive and 55% were negative. The best month was Nov 2023 with a return of +193.1%, while the worst month was Nov 2025 at -86.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.
On a daily basis, KRRO closed higher 48% of trading days. The best single day was Oct 16, 2024 with a return of +93.7%, while the worst single day was Nov 13, 2025 at -79.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 66.42% | -9.00% | -6.68% | 19.17% | -0.59% | -1.72% | -21.32% | 29.46% | |||||
| 2025 | -10.38% | -26.52% | -30.55% | 1.95% | -35.66% | 9.37% | 19.78% | 54.28% | 107.50% | -14.58% | -86.07% | 40.53% | -78.96% |
| 2024 | 6.01% | -4.94% | 86.34% | -36.90% | -9.67% | -33.98% | 37.47% | 2.49% | -29.97% | 72.05% | -9.46% | -26.87% | -20.57% |
| 2023 | 193.08% | 14.36% | 235.17% |
Benchmark Metrics
Frequency Therapeutics Inc has an annualized alpha of 54.24%, beta of 1.89, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since November 06, 2023.
- This stock participated in 290.51% of S&P 500 Index downside but only 80.02% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 54.24%
- Beta
- 1.89
- R²
- 0.05
- Upside Capture
- 80.02%
- Downside Capture
- 290.51%
Return for Risk
Risk / Return Rank
KRRO ranks 44 for risk / return — above 44% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Frequency Therapeutics Inc (KRRO) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KRRO | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.67 | ||
| Sortino ratioReturn per unit of downside risk | -1.10 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.25 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | -0.34 | 2.00 | -2.35 |
| Martin ratioReturn relative to average drawdown | -0.46 | 8.49 | -8.95 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Frequency Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Frequency Therapeutics Inc was 94.13%, occurring on Dec 2, 2025. The portfolio has not yet recovered.
The current Frequency Therapeutics Inc drawdown is 88.48%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-94.13%Dec 2025 | 1y 8mo | — | 2y 4moApr 2024 - now | — |
-32.22%Feb 2024 | 22d | 26d | 1mo 18dFeb 2024 - Mar 2024 | — |
-29.28%Jan 2024 | 1mo 14d | 18d | 2mo 2dDec 2023 - Feb 2024 | — |
-26.17%Nov 2023 | 13d | 7d | 20dNov 2023 - Dec 2023 | — |
-0.68%Nov 2023 | 1d | 1d | 1dNov 2023 - Nov 2023 | — |
Drawdown Indicators
| KRRO | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.13% | -56.78% | -37.35% |
Max Drawdown (1Y)Largest decline over 1 year | -89.72% | -9.10% | -80.62% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -88.48% | -1.58% | -86.90% |
Average DrawdownAverage peak-to-trough decline | -60.60% | -10.70% | -49.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 66.76% | 2.14% | +64.62% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Frequency Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Frequency Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for KRRO relative to other companies in the Biotechnology industry. Currently, KRRO has a P/S ratio of 27.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KRRO in comparison with other companies in the Biotechnology industry. Currently, KRRO has a P/B value of 1.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KRRO
Add Frequency Therapeutics Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KRRO